Stipulating bid invitation units build up this year's bid plan price based on the bid winning result of the previous 12 months (one year) is unreasonable because: (1) Under the proposed bid-winning price must always be lower if the regulation is implemented continuously, it will come at a time the plan price will be lower than the price of the product, which will lead to many big manufacturers, high technology investment always take medicinal quality and effective treatment to ensure the brand of their business will not have the opportunity to participate in the bid, cause double disadvantages for both drug users (Doctors, Patients) and businesses; (2) This provision only "Prioritizes drug discounts" without taking into account the interests of drug users and businesses. Therefore, domestic manufacturers are not encouraged to invest in equipment, machinery, new technology, renovate or build new plants with higher standards such as EU - GMP and / or PIC'S - GMP. has been approved by the Prime Minister in "Vietnam Pharmaceutical Development Strategy to 2020 vision 2030". On the other hand, the cost of products depends on many factors: cost of raw materials, salaries, and other production costs. As input factors increase, manufacturers must also adjust prices to ensure product quality and operation of the business.